| abstract |
Compounds, methods and pharmaceutical compositions are provided for reducing the amount or activity of ATXN3 mRNA in a cell or animal, and in certain instances, reducing the amount of Ataxin-3 protein in a cell or animal. Such compounds, methods and pharmaceutical compositions are useful for preventing or ameliorating at least one symptom or characteristic of a neurodegenerative disease. Such symptoms and characteristics include ataxia, neuropathy, and aggregate formation. Such neurodegenerative diseases include SCA3. [Selection figure] None |